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Abstract 
Background: Fluorescent silica nanoparticles have been extensively utilised in a 
broad range of biological applications and are facilitated by their predictable, well-
understood, flexible chemistry and apparent biocompatibility. The ability to couple 
various siloxane precursors with fluorescent dyes and to be subsequently incorporated 
into silica nanoparticles has made it possible to engineer these fluorophores-doped 
nanomaterials to specific optical requirements in biological experimentation. Conse-
quently, this class of nanomaterial has been used in applications across immunodiag-
nostics, drug delivery and human-trial bioimaging in cancer research.
Main body: This review summarises the state-of-the-art of the use of dye-doped silica 
nanoparticles in bioapplications and firstly accounts for the common nanoparticle syn-
thesis methods, surface modification approaches and different bioconjugation strate-
gies employed to generate biomolecule-coated nanoparticles. The use of dye-doped 
silica nanoparticles in immunoassays/biosensing, bioimaging and drug delivery is then 
provided and possible future directions in the field are highlighted. Other non-cancer-
related applications involving silica nanoparticles are also briefly discussed. Importantly, 
the impact of how the protein corona has changed our understanding of NP interac-
tions with biological systems is described, as well as demonstrations of its capacity to 
be favourably manipulated.
Conclusions: Dye-doped silica nanoparticles have found success in the immunodiag-
nostics domain and have also shown promise as bioimaging agents in human clinical 
trials. Their use in cancer delivery has been restricted to murine models, as has been 
the case for the vast majority of nanomaterials intended for cancer therapy. This is ham-
pered by the need for more human-like disease models and the lack of standardisation 
towards assessing nanoparticle toxicity. However, developments in the manipulation of 
the protein corona have improved the understanding of fundamental bio–nano inter-
actions, and will undoubtedly assist in the translation of silica nanoparticles for disease 
treatment to the clinic.
Keywords: Microporous, Silica nanoparticle, Dye loading, Cancer, Toxicity, Protein 
corona, Immunoassay, Diagnostics, Bioimaging, Drug delivery
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Background
As technological capacities continue to progress, scientists have made an increasing 
number of discoveries of molecular mechanisms underlying biological processes. This 
is largely due to the identification of specific intracellular events and protein–receptor 
interactions, e.g. antigen–antibody recognition. Endeavours in biotechnology are now 
therefore focussed on the detection and monitoring of particular chemical interactions 
of small targets that occur at low concentrations, such as individual cells (Maltez-da 
Costa et al. 2012), nucleic acids (Xiao et al. 2007), proteins (Giovannini and De Angelis 
2019) and small molecules (Porchetta et al. 2012). The requirement to detect such enti-
ties has ultimately led to the development of similarly sized probes and, consequently, 
modern biological applications are now highly multidisciplinary and encompass a range 
of physiochemical fields like colloidal science, materials science and supramolecular 
chemistry for detecting, monitoring, and treating diseases.
A variety of new materials have been developed for nano-biotechnological purposes 
and nanoparticles (NP) are by far the most versatile and heavily studied class of nano-
material. Numerous terms for ‘nanoparticle’ have been defined by various national 
and international regulatory bodies and typically require a material to have at least 
one dimension to be between 1 and 100 nm (Miernicki et  al. 2019). However, despite 
these definitions, many researchers regularly use the term ‘nano’ to refer to materials 
with dimensions below 1 µm. In fact, the plethora of NP compositions and architectures 
reported in the literature has led to the term ‘nanoParticle Zoo’ being coined to describe 
the current state of the field (Moore et al. 2015). The nanoParticle Zoo contains different 
materials [gold (Adnan et al. 2016), carbon (Wanga and Hu 2014), quantum dots (Alivi-
satos 1996), silica (Moore et al. 2015), liposomes (Chang and Yeh 2012), iron oxide (Dan-
hier et  al. 2010), etc.] with different shapes [spheres (Wang et  al. 2011a), rods (Yasun 
et al. 2015), plates (Cai and Lin 2014), cages (Chen et al. 2007), stars (Nehl et al. 2006), 
worms (Park et al. 2008), onions (Bartolome et al. 2015), etc.] and different properties 
[plasmonic (Lukianova-Hleb et  al. 2012), fluorescent (Wolfbeis 2015), magnetic (Lee 
et al. 2010), etc.], an array of materials that is challenging to categorise. In light of this 
scenario, we liken this current situation to that of the original Particle Zoo: the scenario 
faced by physicists in the middle of the twentieth century when new elementary parti-
cles were discovered with such regularity, thus requiring classification, that Wolfgang 
Pauli was prompted to supposedly remark “Had I foreseen this, I would have gone into 
botany”.
Dye-doped silica NPs (DDSNs) have emerged as a potential fluorescent nanoprobe 
capable of being adapted to a multitude of bioapplications that offer fluorescent capabili-
ties comparable to heavy metal QDs (which are generally classified as toxic). DDSN syn-
thesis is straightforward and versatile enough to allow for different dyes and drugs to be 
housed in the silica matrix while still allowing for control over the resulting NP size and 
shape. In addition, their adaptable and well-understood chemistry allows a simple and 
straightforward modification of the NP surface chemistry to provide reactive sites for 
further functionalisation (Bagwe et al. 2006; Nooney et al. 2012). Indeed, other classes 
of NP are often coated with a thin layer of silica to improve NP biocompatibility and 
to provide a flexible platform upon which to conduct further reactions (Ma et al. 2014; 
Kobayashi et al. 2003; Gnanasammandhan et al. 2016). Furthermore, silica also does not 
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absorb visible light and doping the silica matrix, embedded with photoactive molecules 
(either internally or bound on the NP surface), allows the NPs to exhibit photophysi-
cal properties similar to those of the chromophores (Yan et  al. 2007; Bae et  al. 2012). 
From a practical perspective, DDSNs exhibit a high density and can therefore be easily 
isolated into an aggregated pellet via centrifugation (Wang et al. 2008; Bae et al. 2012). 
The aggregated mass can be separated from the supernatant easily and ultrasonication 
is then usually required to effectively re-disperse back to their original monodispersed 
state (Bagwe et al. 2006).
This review discusses the advances in the field of DDSN in bioapplications and is pri-
marily focused on microporous silica. Micropores are less than 2 nm in size (McCusker 
et  al. 2001) and we have intentionally avoided referring to mesoporous silica, which 
exhibit 2–50 nm pores and are commonly used as a drug delivery nanomaterial (Li et al. 
2012). We begin with a thorough overview of the two common routes of silica NP syn-
thesis: Stöber and reverse microemulsion methods. The process of dye-doping is then 
discussed, followed by surface functionalisation strategies and how DDSN surface chem-
istry influences colloidal stability. The developments in the use of DDSNs in biosens-
ing, bioimaging and drug delivery are then presented, and are predominantly focused on 
cancer research. Importantly, the impact of the protein corona on understanding DDSN 
interactions with biological systems is also discussed and its implications in in vitro and 
in vivo studies are highlighted. This article concludes with a discussion on silica NP tox-
icity and how a lack of widely accepted approaches to nanotoxicology can result in con-
flicting experimental outcomes.
Silica nanoparticle synthesis
Silica NPs are usually generated using the sol–gel method and involves the hydrolysis, 
and subsequent condensation, of alkoxide precursors via acid or base catalysis. Tetra-
ethyl orthosilicate (TEOS) is typically employed as a silica precursor. Base catalysis of 
silica precursors with ammonia is the most commonly used approach for NP generation 
(Fig. 1).
The most widely used synthetic strategies are the Stöber method and the reverse 
microemulsion method, both of which have their own advantages and disadvantages. As 
Fig. 1 Base-catalysed hydrolysis/condensation of silica precursors. Tetraethyl orthosilicate (TEOS) is the most 
commonly used precursor for generating silica nanoparticles
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means of creating luminescent NPs, dyes are typically functionalised with trialkoxysi-
lanes such that they can be incorporated in the silica matrix during particle formation 
alongside TEOS, and this doping process can influence the resultant NP size (Nooney 
et al. 2012). Covalent attachment of dyes reduces dye leaching from the NP in compari-
son to when dyes are physically entrapped in the silica matrix, but it should be noted 
that covalent attachment does not completely prevent leaching as silica NPs can degrade 
in biological conditions, which is a feature frequently overlooked by researchers (Mahon 
et al. 2012b).
Stöber method
The Stöber method, first described in the 1960s (Stöber et al. 1968), involves the hydrol-
ysis and condensation of a silica alkoxide precursor, typically TEOS, in a water/alcohol 
mixture catalysed by the addition of ammonium hydroxide (Fig.  2a) (Bonacchi et  al. 
2011). This synthetic route to control important parameters of the resultant NPs, such 
as size, porosity and colloidal stability by controlling a range of synthetic parameters 
such as precursor concentration (Huang and Pemberton 2010), reaction time (Yokoi 
et al. 2009), temperature (Huang and Pemberton 2010), stirring conditions (Yokoi et al. 
2009) and the potential use of multistep regrowth procedures for controlled NP growth 
(Hartlen et al. 2008). Notable advantages of this method are that it is straightforward to 
perform, it produces particles in the 50 nm–2 μm range and it can be upscaled. There-
fore, the Stöber approach is widely used for multiple applications and when producing 
silica NPs for commercial applications. However, precise control of NP monodispersity 
and morphology can be problematic, with < 30 nm diameter NPs being challenging to 
synthesise (Wang et al. 2011a). The mechanism for NP formation remains unclear, with 
two models favoured by the scientific community (Korzeniowska et al. 2013). The first, 
proposed by LaMer and Dinegar described a ‘monomer addition’ situation where two 
distinct steps occur during synthesis: an initial burst of nucleation to form primary par-
ticles, followed by particle growth due to the addition of hydrolysed monomers to the 
primary particle surface (LaMer and Dinegar 1950; Matsoukas and Gulari 1989). The 
second model suggested by Bogush and Zukoski (1992) describes the continuous nucle-
ation during the reaction where of primary sub-particles ‘aggregate’ into larger particles 
(Ab Rahman and Padavettan 2012).
Fig. 2 Common approaches to silica nanoparticle synthesis. The two main synthetic approaches used for 
the formation of silica NPs are a the Stӧber method and b the reverse microemulsion method (adapted from 
Bonacchi et al. (2011))
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Variations on the Stöber method have also been reported. Wiesner and co-workers 
reported a modified Stöber method that first involved the formation of dye-loaded 
‘seeds’ that were later covered by a denser silica network to give a fluorescent core–shell 
configuration (Burns et al. 2006; Ow et al. 2005). The shell protects the dye-loaded core 
from interactions with the surrounding solvent, thus enhancing particle photostability 
and brightness. These NPs were dubbed Cornell dots (C-dots). A second generation of 
silica NPs, termed Cornell prime dots (C′-dots), have since been developed and involves 
water-based synthesis of sub-10  nm polyethylene glycol (PEG)-coated silica NPs (Ma 
et  al. 2015). Using tetramethyl orthosilicate (TMOS) as a precursor, NP growth could 
be controlled by a number of factors such as the introduction of silane-functionalised 
PEG to the NP surface to cap particle growth. This in turn provided a functional sur-
face supporting NP stability through steric interactions. In addition, the inclusion of 
an aluminium alkoxide precursor into the NP core enhanced the quantum yield of the 
encapsulated near-infrared dyes. C-dots and C′-dots have reported positive results from 
human clinical trial trials for in vivo tumour imaging (Phillips et al. 2014).
Reverse microemulsion method
The second method of silica NP formation is the water-in-oil reverse microemulsion 
(Fig. 2b) (Bonacchi et al. 2011). Here, surfactant-stabilised water droplets are dispersed 
in an oil phase to create micelles that serve as a ‘nanoreactor’ for the confined nuclea-
tion and growth of silica NPs. TEOS diffuses into the water phase (which also contains 
ammonia catalyst), and undergoes hydrolysis and condensation. Micelles collide and 
exchange nuclei and/or hydrolysed monomers, thus promoting NP growth (Finnie et al. 
2007). The factors that govern the resultant NP include the water-to-surfactant ratio, 
concentration of ammonium hydroxide, and concentration of TEOS (Arriagada and 
Osseo-Asare 1999b). Bagwe et al. (2004) conducted a thorough study of these param-
eters to examine how they can influence size and polydispersity of [Ru(bpy)3]2+-doped 
NPs. One particular finding involved the choice of surfactants of different natures (e.g. 
linear or branched, with or without charge) to show that micelle structure and rigidity 
can govern their collision dynamics, thus controlling the nucleation and growth mech-
anism in a given water-in-oil system. Consequently, NPs of different sizes were pro-
duced. The reverse microemulsion method has been heavily studied by Arriagada and 
Osseo-Asare (1995, 1999b) with one their important works being the development of 
a statistical nucleation model to accurately describe silica NP formation in water-in-oil 
microemulsions (Arriagada and Osseo-Asare 1999a). Under similar synthesis condi-
tions, the use of fluorescein isothiocyanate (FITC) produced larger NPs than fluorescein 
succinimidyl ester-doped particles. It was thought that due to fluorescein succinimidyl 
ester being less soluble in the water nanodroplets of the microemulsion, the supersatura-
tion concentration was lowered.
This led to an increase in the number of nucleating sites, which in turn led to the for-
mation of smaller NPs. In general, smaller monodisperse NPs (approx. 15–50 nm) can 
be produced using the reverse microemulsion method in comparison to traditional 
Stöber approaches. However, this synthetic approach is limited by the excessive use of 
organic solvent and surfactants (which can remain on the NP surface following purifi-
cation). The need for excessive purification and solvent-cost therefore limits upscaling. 
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The reverse microemulsion system is well-suited for preparing other nanomaterials with 
silica shells. Creating a silica shell around quantum dot cores, for example, is used to 
offset the cytotoxic effects attributed to their heavy metal composition, thereby improv-
ing their biocompatibility and usefulness in bioimaging (Montalti et al. 2014). Creating 
a layer of silica around such NPs also lends itself to easier functionalisation with orga-
nosilanes bearing reactive functional groups (Wegner and Hildebrandt 2015). The main 
advantages and disadvantages of the Stöber and reverse microemulsion methods are 
listed in Table 1.
Other methods
The direct micelle-assisted method is another method that has grown in popularity as 
it allows for one-pot synthesis of PEGylated DDSNs, thus eliminating the need for later 
surface functionalisation (Montalti et  al. 2014). Pluronic 127, a tri-block PEG–PPO–
PEG (poly(ethylene–glycol)–poly(propylene oxide)–poly(ethylene glycol)) is used as 
high molecular weight surfactant to form micelles. The relatively polar PPO inner core 
of the micelle allows lipophilic TEOS to be used as a precursor. Particle synthesis is then 
acid catalysed, using hydrochloric acid (Liu et al. 2009; Huo et al. 2006) or acetic acid 
(Rampazzo et  al. 2012), and particle growth is confined to the micellar environment. 
The hydrophilic PEG moieties are directed outwards from the NP surface and ultimately 
results in silica-PEG core–shell architecture. By derivatising dyes with alkoxysilanes, it is 
then possible to covalently dope fluorophores into the particle core. Silica NPs generated 
using the direct micelle-assisted method have since been dubbed PLuS NPs (Pluronic 
silica NPs) (Pedone et al. 2013).
Dual-phase approaches for controlling the growth of small (10–100  nm) NPs have 
recently come to prominence (Wang et al. 2011a; Hristov et al. 2015a). An upper organic 
phase containing TEOS controls the transfer of the precursor to a catalyst-containing 
aqueous phase where NPs are grown and leads to greater control of NP size. Hristov 
et  al. (2015a), for example, used organic solvents of different polarity (ethanol, iso-
propanol, 1-butanol, 1-hexanol and cyclohexane) to control the transfer rate of TEOS 
monomers to the aqueous phase. This in turn governed the rate of hydrolysed monomer 
generation and the controlled production of NPs in the 10–100 nm range.
Table 1 The advantages and  disadvantages of  the  Stöber and  reverse microemulsion 
method
Stöber Reverse microemulsion
Advantages Disadvantages Advantages Disadvantages
Water-based synthesis 
possible
Greater NP polydispersity 
than reverse microemul-
sion
Precise control of NP size Excessive use of organic 
solvents
Surfactant-free Challenging to produce 
sub-30 nm NPs
Small NPs (20–200 nm) Residual surfactant on 
NP surface following 
purification
Favoured for upscaling 
(gram scale)
Not suited to upscaling 
(milligramme scale)
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Organically modified silica (ORMOSIL) NPs are another class of silica NPs that typi-
cally employ alkyl-substituted silicon alkoxides as precursors to modify the silica net-
work, which facilitates the incorporation hydrophobic materials into the NP (e.g. dyes or 
chemotherapeutics). For example, the use of phenyltrimethoxysilane and methyltrimeth-
oxysilane as precursors for the entrapment of porphyrins, and subsequently allowed for 
the development of a dual-dye sensor for intracellular dissolved oxygen detection (Koo 
et al. 2004). ORMOSIL NPs have since become used in vivo imaging and drug delivery 
applications (Ohulchanskyy et al. 2007; Kumar et al. 2010; Roy et al. 2014; Nagesetti and 
McGoron 2016).
Though less popular, non-spherical silica nanomaterials can also be generated. Imhof 
and co-workers have demonstrated the possibility to generate bullet-like silica rods 
through a one-pot synthesis containing ethanol, water, sodium citrate and ammonia in a 
solution of polyvinylpyrrolidone (PVP) in pentanol (Kuijk et al. 2011). Rods with diam-
eter 200–300 nm and lengths of up to 10 µm could be produced using this method. Due 
to the straightforward chemistry of silica, it was also possible to label the rods with fluo-
rescent dyes. It was later possible to etch rod-like particles into cone-like particles using 
ammonium hydroxide (Hagemans et al. 2016). This work was further extended to show 
that spheres and rods could be etched into dumbbells and biconcave silica rings sand-
wiched between two silica spheres (Hagemans et  al. 2017). Silica ‘matchstick’ colloids 
have also been reported (Longbottom et al. 2015).
Dye encapsulation
Dye molecules can be incorporated into the silica matrix by two means: physical 
entrapment or covalent attachment. Positively charged dyes, such as tris(bipyridine)
ruthenium(II) chloride, [Ru(bpy)3]2+, are well-suited for physical entrapment into the 
negatively charged silica network, but covalent linking is preferred because it min-
imises dye leakage from the NP over time. The first report of covalent attachment of 
dye molecules into the matrix of silica NPs was by van Blaaderen and Vrij in 1992 (Van 
Blaaderen and Vrij 1992). This involved the coupling of FITC to an oxysilane coupling 
agent (3-aminopropyl) triethoxysilane (APTES), via a thiourea bond and the controllable 
incorporation of the FITC–APTES reaction product into the silica structure.
In general, obtaining NPs of maximal brightness is desirable as it enables high sen-
sitivity and the detection of low concentration analytes. The choice of fluorophore is 
central to achieving this goal and is application dependent. For example, one must con-
sider the fluorophore’s excitation and emission wavelengths. The dyes used should ide-
ally be readable by common laser lines to facilitate their use in biomedical diagnostics 
and bioimaging. For this reason, fluorescein is often employed as it can be excited at 
488  nm by standard argon lasers employed in confocal microscopy and flow cytome-
try. Near infrared (NIR) labels are advantageous for use in applications incorporating 
whole blood as blood exhibits a weak absorption band. This is important as it reduces 
the need for sample filtering and allows for more straightforward biosensor design 
(Korzeniowska et  al. 2013). In  vivo imaging is also possible using near infrared (NIR) 
dyes. For example, Wiesner’s C-dots incorporate Cy5, in conjunction with PET probes, 
for non-invasive NP imaging/tracking (Phillips et  al. 2014; Benezra et  al. 2011). How-
ever, commercially available near infrared dyes are on the order of $200–$300/mg (Ma 
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et al. 2015) and demonstrates that the choice of dye can be cost-dependent as well as 
application-dependent.
Creating NPs with optimal brightness is another point of consideration when develop-
ing DDSNs. This is largely associated with the concentration of dye molecules bound 
inside the silica matrix (Fig. 3) (Battistelli et al. 2016). If too few fluorophores are encap-
sulated inside the core then the resultant NP may insufficiently bright. Interestingly if 
too many dyes are densely packed inside the silica core, the overall brightness might be 
reduced through self-quenching (Fig. 3a, b). The reduced NP fluorescence intensity due 
to dye overloading can be attributed to Förster resonance energy transfer (FRET), fluo-
rophore aggregation and inner filter effects (Miletto et al. 2012; Battistelli et al. 2016).
Commonly used dyes in biological applications, such as fluorescein, exhibit large 
excitation and emission overlap (small Stokes shift) and if situated in close proxim-
ity to one another FRET can occur. If two of the same dye molecule are in proxim-
ity of each other and experience FRET, this phenomenon is known as homo-FRET 
or self-quenching. Studies have therefore focused on the optimisation of dye loading 
into silica NPs (Imhof et al. 1999; Nooney et al. 2009). Nooney et al. (2009) addressed 
this issue by developing a dye loading model for the optimisation NP fluorescence in 
relation to concentration of NIR-664 succinimidyl ester loading into the NP core. One 
way of circumventing the issue of homo-FRET is by choosing fluorophores with large 
Stokes shift such that their excitation and emission wavelength do not greatly overlap 
(Herz et al. 2009). For example, Hell and co-workers used large Stokes shift dyes with 
greater than 140 nm absorbance/emission maxima separation for stimulated emission 
depletion (STED) microscopy for cellular labelling (Butkevich et al. 2017). However, 
Fig. 3 Optimising dye loading is crucial to achieving maximal NP brightness. a (left) A low number, n, of 
fluorophores present in the NP maximises quantum yield, φ, but NP brightness, B, is low. a (right) A high 
concentration of fluorophores can lead to FRET/self-quenching and result in a low brightness NP. The optimal 
loading window in shown in blue. b Left: ideally, self-quenching and FRET can be minimised by controlling 
dye distribution or, b (right) using molecules with large Stokes shift such their proximity is not problematic. 
c Absorbance spectrum of silica NPs doped with different FITC:Rhodamine6G:ROX ratios. d Different 
dye-doping ratios could generate silica NPs with different fluorescent signatures (a, b adapted from Battistelli 
et al. (2016); c, d adapted from Wang and Tan (2006))
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such dyes are usually expensive in comparison to common fluorophores and are yet to 
gain widespread use.
Despite these considerations, the issue of self-quenching is not always regarded as a 
disadvantage when it comes to formulating DDSNs. For example, Moore et al. used fluo-
rescein-overloaded silica NPs to improve immunoassay fluorescent signals. The dye was 
intentionally overloaded into silica NPs such that self-quenching reduced NP brightness, 
but following antigen recognition the NPs were degraded using basic buffer. This led to 
the release of the fluorescent cargo from the NPs and the liberation of the fluorophores 
from self-quenching. Coupled with the fluorescein’s increased brightness in basic condi-
tions, the large quantity of free dye exhibited an order of magnitude increase in fluores-
cent signal compared to traditionally used NPs loaded with optimum quantities of dye 
(Moore et al. 2017).
Tan et al. exploited FRET by ratiometrically encapsulating FITC, Rhodamine 6G and 
ROX into silica NPs to create silica NPs with specific fluorescence signatures under sin-
gle wavelength excitation (Wang and Tan 2006). The use of dyes with overlapping exci-
tation and emission wavelengths allowed for large Stokes shifts to be produced. For 
example, doping the three fluorophores in 1:1:1 ratio made it possible to use FITC exci-
tation (490 nm) to produce emission around 608 nm (i.e. ROX emission) caused by the 
donor–acceptor cascade between the individual dye absorbance and emission bands. 
The generation of multicolour silica NPs made them suitable for multiplex analysis 
(Fig. 3c, d).
Doping silica NPs with fluorescent organic molecules has also been shown to be use-
ful in elucidating the structural integrity of the internal particle matrix over time. Daw-
son and co-workers adsorbed thioflavin T into Stöber-synthesised NPs and exploited 
the rotor-based fluorescence of the molecule. Intact silica NPs restricted the rotational 
freedom of thioflavin T which results in fluorescence spectrum red-shifting. The mol-
ecule regained rotational freedom following NP degradation and resulted in a reduction 
of fluorescence emission of up to three orders of magnitude, thus serving as an indicator 
of matrix integrity. The use of thioflavin T-doped silica NPs was then used to track NP 
structural integrity in in vitro experiments (Meder et al. 2016).
Computational approaches to analysing surface chemistry can also be employed as 
tools to achieve a better understanding of synthesised NPs. For example, interactions of 
salts (de Lara et al. 2012, 2015) and polymers (Hong and Panagiotopoulos 2012) with the 
surface of silica can be modelled, as well as interactions with proteins (Sun et al. 2014). 
The outcome of controlled approaches to silica NP synthesis has also been possible to 
verify using computation simulations (Suzuki et al. 2010).
Overall, silica NPs are a flexible platform upon which fluorescent particles can be pro-
duced without great synthetic efforts. However, it is important to consider the intended 
application of the NPs and the overall cost of production prior to experimentation since 
this will determine the choice of dye and the most appropriate synthetic route. Covalent 
binding of dyes inside the silica matrix will retain fluorophores inside the particle core 
longer than those physically entrapped (Korzeniowska et al. 2013). Particle dissolution 
occurs in aqueous media and can result in dye leaching, which means storing NPs in 
solvents like ethanol is preferred. DDSNs can even be stored in gels for longer-term stor-
age (Giovannini et  al. 2017). Dye leaching can be monitored using simple techniques 
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like dialysis, whereby free dye can be separated from NPs and then optically quantified. 
Transmission electron microscopy can also be used to examine dissolution-induced NP 
hollowing/etching (Giovannini et  al. 2018a). Stabilising DDSNs against dissolution in 
aqueous media is therefore advised before biological experimentation as the release of 
free dye can lead to misleading experimental outcomes (Mahon et al. 2012b).
Surface chemistry
Post‑synthesis NP coating
An unmodified and pristine silica NP is inherently negatively charged due to surface 
hydroxyls, but other more reactive groups are usually added to the NP exterior following 
synthesis. Functional groups such as thiols (Claesson and Philipse 2007), epoxy (Zhang 
et al. 2009), vinyl (Sharma et al. 2004) and amines (Bagwe et al. 2006) can be introduced 
by adding alkoxysilane derivatives (Wang et al. 2008; Malba et al. 2014). These functional 
groups aim to render the surface neutral or introduce charge, which in turns provide 
advantages such as increased biocompatibility, supramolecular recognition or simply 
serve as reactive sites for future linker or biomolecule attachment.
Amine modification is widely used because it allows for later reactions with alde-
hyde- or NHS ester-functionalised biomolecules, linkers, or dyes. The most popular, 
inexpensive and commercially available reagents for amine surface treatment are amino-
propyltrimethoxysilane (APTMS) and aminopropyltriethoxysilane (APTES). NP surface 
treatment with APTES can be performed in situ where the aminoalkoxysilane is intro-
duced in the later stages of polymerisation within the Stöber process once the nuclei are 
formed (An et al. 2007). In such cases the aminoalkoxysilane reagent is typically used in 
excess and any unreacted molecules are removed during the purification steps.
However, despite being considered efficient, this strategy can lead to formation of dis-
ordered multi-layers since the degree of surface modification depends on multiple fac-
tors such as solvent used, water content, temperature, reaction time, etc.
Additionally, there are several possible modes of attachment/association of APTES 
with a silica surface caused mainly by hydrogen bonding, other non-covalent interac-
tions or vertical polymerisation. In addition, homogenous amine modification of the 
silica surface is generally challenging because aminoalkoxysilanes in solution are prone 
to uncontrolled polymerisation (Fig.  4A) (Zhu et  al. 2012; Smith and Chen 2008). To 
achieve uniform amine monolayers it is therefore necessary to carefully control reaction 
conditions (Schulz et  al. 2011) and the amount of APTES used (Hristov et  al. 2015b). 
An interesting study by Chen and Smith compared commercially available short- and 
long-chained aminoalkoxysilane derivatives (5, 8, 10 Å chain length) and examined their 
ability to be removed from the silica NP surface through intra or intermolecular self-
cleavage (Fig. 4B, C) (Smith and Chen 2008). The authors found that the amine func-
tionality can be lost on silica surface over time because the primary amine in the propyl 
position of APTMS and APTES is capable of coordinating with silicon atoms either 
intramolecularly (via the formation of a five-membered cyclical intermediate) or inter-
molecularly and catalyses the cleavage of the siloxane bonds via hydrolysis (Fig.  4B). 
However, N-(6-aminohexyl)aminomethyltriethoxysilane-derived surfaces were more 
resistant to hydrolysis and produced stable amine-functionalised silica surfaces due to 
longer chain length being incapable of intramolecular coordination with silicon atoms 
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(Fig. 4c), thus suggesting that longer chained aminoalkoxysilanes may retain amine func-
tionality on silica for longer.
Successful amine modification is usually confirmed by the change in zeta potential, but 
does not quantify the functional groups surface density (this is important for toxicologi-
cal studies as amine-modified materials can increase cytotoxicity) (Shahabi et al. 2015). 
Acid–base titration (Jung et al. 2012), colorimetric or fluorescent reactions (Chen and 
Zhang 2011; Noel et al. 2011), thermogravimetric analysis (Lu 2013), or solution (Hris-
tov et  al. 2015b; Kunc et  al. 2018) or solid-state NMR (Sun et  al. 2019) are examples 
of quantitative methods used to accurately characterise the content of amine and other 
functional groups on silica NPs surface.
It should be noted that these methods vary in their sensitivity and the ranges of 
applicability. The choice of method will depend on given the functional group. Reac-
tive chemical groups such as amines or thiols can be quantified by chemical assays, 
these however require extensive optimisation since their output may not be quantita-
tive (Sun et al. 2019). Thermogravimetric analysis is typically less sensitive and hence 
more applicable for the analysis of thick polymer coatings. This is because for silica 
NPs, TGA is further complicated by the interference arising from the co-condensa-
tion of silanol hydroxyls occurring throughout the whole temperature gradient. Solid-
state NMR is limited by the high amount of material and the long measurement time 
required for analysis of less abundant 13C. This may be overcome by labelling by iso-
tope labelling, if applicable. For silica NPs, solution NMR appears as the most facile 
method for total quantification of functional groups, however, this depends on the 
functional group solubility aqueous media (Kunc et al. 2018).
Post-synthesis coatings of silica NPs with amine-reactive moieties can promote col-
loidal stability via electrostatic repulsion, but it should be noted that such stability 
is dependent on, for example, pH. Amine groups on the NP surface can be proto-
nated (–NH3+) positively charged in physiological pH, whereas the silica matrix is 
Fig. 4 Post-coating unmodified –OH bearing silica NPs is commonly done using siloxanes with reactive 
amines. A However, such coatings are not usually homogenous and individual silane molecules can interact 
through (a) hydrogen bonding, (b) electrostatic attraction, (c) covalent bonding with surface, (d) horizontal, 
and (e) vertical polymerisation with neighbouring silanes. (f ) Oligomeric/polymeric silanes can also react/
interact with functionalities present at the interface. B When the reactive amine is in the propyl position it can 
coordinate intra- or intermolecularly with silicon atoms and catalyse the cleavage of the siloxane bond via 
hydrolysis, thus eventually resulting in the loss of amine groups from the silica surface. C The longer chains of 
N-(6-aminohexyl)aminomethyltriethoxysilane are not capable of self-cleave and give stable amine layers on 
silica surfaces (A: adapted from Zhu et al. (2012); B, C: adapted from Smith and Chen (2008))
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negatively charged in such conditions (Bagwe et  al. 2006). Consequently, a reduc-
tion in the surface charge of the NP occurs and means NP–NP repulsion is reduced, 
thus giving rises to aggregation. A notable study by Bagwe et al. (2006) showed how 
a combination of negatively charged ‘inert’ phosphonate groups and ‘reactive’ amine 
groups can be combined on the surface of RuBpy-doped silica NPs to reduce particle 
aggregation, while also still providing the reactive sites needed for later functionalisa-
tion. ‘Bipodal’ bis amine[3-(triethoxysilyl) propyl] has also been proposed as an alter-
native to traditional ‘monopodal’ APTMS as the former produces more colloidally 
stable amine-coated silica NPs (Kelleher et al. 2015). Wang et al. demonstrated that 
silica NPs can also be used as a platform for catalysis and was facilitated by the use 
of amino-functionalised colloids. The amino groups served as a template upon which 
a series of intermediate functionalisations could be carried out and ultimately yield 
TEMPO-coated silica NPs capable of benzylic alcohol oxidation (Liu et al. 2015).
Overall, the use of common aminoalkoxysilanes like APTES or APTMS allows for 
silica NPs to be used as a platform upon which advanced functional materials can 
be designed. Nonetheless, as highlighted by this section, researchers should carefully 
consider the coating strategy when attempting to generate amine-functionalised silica 
NPs. Other examples in the literature that summarise silica NP synthesis and func-
tionalisation can be found elsewhere (Wang et al. 2013; Liberman et al. 2014; Mon-
talti et al. 2014).
Bioconjugation strategies
Bioconjugation in the context of nanomaterials means attachment of biomolecules 
(e.g. proteins, enzymes, oligonucleotides, etc.) onto the surface of NPs. Usually it can 
be performed by two methods; passive absorption or covalent attachment (Gubala 
et al. 2018b). Passive adsorption is straightforward to conduct, cost efficient and leads 
to the adsorption of protein layers surrounding the NP surface. However, because the 
biomolecules are not covalently attached they can be removed and replaced by other 
biomolecules that exhibit higher affinity towards the NP surface. For proteins, the most 
frequently used biomolecule for bioconjugation, changes in conformation or local pH 
influence a protein’s isoelectric point and subsequently its electrostatic interactions 
with the NP surface, which can then cause desorption of biomolecule (Korzeniowska 
et  al. 2013). Vertegel and co-workers (2004) also studied how particle size influences 
the structure and activity of protein adsorbed to 4 nm, 20 nm and 100 nm silica NPs. It 
was shown that adsorbing lysozyme to increasingly larger silica NPs leads to increased 
α-helix structural loss, thus causing reduced enzymatic activity. The authors suggested 
that protein–NP interactions increased on the less curved surfaces of the larger NPs and 
resulted in secondary structural loss. The adsorption of cytochrome c to silica NPs of 
different sizes also followed a similar trend (Shang et al. 2009).
The more widely used method of functionalising silica NPs with biomolecules is 
through covalent bond formation, and is typically facilitated by a linker molecule 
(Korzeniowska et al. 2013; Moore et al. 2015). The covalent approach is typically a two-
step process where, firstly, the linker is introduced to the NP surface and, secondly, the 
biomolecule of interest is bound to the NP via the linker. The linker also serves as a 
spacer between the biomolecule and the NP surface, thus allowing the biomolecule to 
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experience greater solvation and reduces potential for misfolding due to NP–biomole-
cule interactions (Korzeniowska et al. 2013; Hristov et al. 2015b). It also allows for desir-
able reactive groups to be imparted to the NP surface prior to the introduction of the 
biomolecule.
Linkers are generally used to bind to specific amino acid residues of an antibody. For 
example, there are approximately 83 lysine residues per whole IgG biomolecule (Tan 
et al. 2008) and these primary amines can be used as reactive sites for covalent attach-
ment using ethyl(dimethylaminopropyl) carbodiimide EDC (EDC)/N-hydroxysuccinim-
ide (NHS) chemistry (Moore et al. 2015; Kunc et al. 2019). While the use of EDC/NHS 
coupling is very popular for bioconjugation, it should be noted that due to the presence 
of amine groups throughout the protein it is therefore not possible to control the orien-
tation of the antibody upon attachment to the NP surface, and can ultimately result in 
binding epitopes that are incapable of recognising their target.
‘Click’ chemistry is an increasingly popular form of bioconjugation that involves reac-
tions of high stereospecificity and high efficiency. In particular, copper-free strain pro-
moted cycloaddition ‘click’ reactions between strained alkynes and azides are well-suited 
for biological applications as they do not require the use of potentially toxic, dye-quench-
ing copper catalysts [which were employed in the original alkyne–azide cycloaddition 
reactions (Rostovtsev et al. 2002; Tornøe et al. 2002)]. One specific requirement for click 
chemistry is the necessity to site-specifically introduce click-reactive groups to the pro-
tein, which are typically inserted distal to the antigen-binding domain (Sivaram et  al. 
2018). However, once achieved, the antigen-binding site of the ‘click’-bound antibodies 
can then become more accessible on the NP surface and, compared to traditional EDC/
NHS that produce randomly orientated antibodies, can improve the overall target-bind-
ing capacity of the protein-functionalised NPs. In addition, the use of ‘click’ reactions for 
bioconjugation (compared to traditional EDC/NHS) offers the possibility to reduce the 
quantity of antibody used per reaction due to high binding efficiencies (Sivaram et al. 
2018).
The nature of the crosslinker has significant effect on the bioconjugation reaction. 
Crosslinkers can be either monovalent or multivalent in nature, and choosing the appro-
priate form depends on different factors like the availability of reactive groups on the NP 
surface, the potential for the linker to induce unwanted NP aggregation, linker commer-
cial availability and the application the NPs are intended for. For example, Gubala et al. 
(2010) showed that, in comparison to monovalent linkers, using multivalent polyami-
doamine (PAMAM) dendrimers for bioconjugation can be used to increase the number 
of binding sites on silica NPs for antibody coupling, and was particularly useful since the 
number of post-coated primary amines on the particle surface was restricted in order 
to maintain colloidal stability. The multiple binding sites afforded by PAMAM-coated 
silica NPs lead to greater number of antibodies being bound compared to monovalent 
glutaraldehyde and sulfo-SMCC. This work was later extended to show that increasing 
PAMAM multivalency, which allowed for greater number of antibodies per NP, leads 
to enhanced immunoassay kinetics when detecting C-reactive protein, a cardiovascu-
lar disease biomarker (Gubala et al. 2011). Multivalent carboxy-dextran has also shown 
to be a potential cost-effective alternative to multivalent PAMAM for bioconjugation of 
antibodies to DDNPs (Kunc et al. 2019).
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Polyethylene glycol is a linker molecule frequently used to functionalise NPs for 
drug delivery applications (Allen and Cullis 2013) and is rationalised by the strategy of 
improving the circulation half-life of NPs in vivo to exploit the enhanced permeability 
and retention (EPR) effect for localising in tumour sites (He et  al. 2008). Controlling 
the density of PEG on the NP surfaces to form ‘brush-like’ conformations appears to be 
a crucial factor that determines the ability of NPs to evade immune cell uptake and to 
impart ‘stealth’ properties (Adumeau et al. 2017; Yang et al. 2014).
The polymer is commercially available in a variety of forms (short chained, polymeric 
or hyper-branched) and is highly hydrophilic, neutrally charged and biocompatible. It 
can also be bought with a wide range of functionalities and therefore allows for biomol-
ecule attachment, thus combining ‘stealth’ and ‘targeting’ into a single colloidal system 
(Alric et  al. 2016). A noteworthy example of dual stealth/targeting are Wiesner’s sub-
10 nm DDSNs that underwent human clinical trials and utilise PEG functionalised with 
targeting peptides (Phillips et al. 2014; Benezra et al. 2011). Interestingly, the mechanism 
of PEGylation of these small NPs (achieved using a PEG-silane) has been elucidated 
using fluorescence correlation and cross-correlation spectroscopy (Ma et al. 2016).
Firstly, the PEG-silane non-covalently associates with the silica surface (presum-
ably through hydrogen bonding), followed by the accelerated condensation of the 
PEG-silane on the particle due to the molecule’s proximity to the NP surface. This 
functionalisation mechanism allowed for the rapid transition between NPs stabilised 
through electrostatic repulsion to those stabilised through steric interactions, thus 
providing monomodal NPs. When NPs exhibited a low PEG density on NP surface, 
electrostatic stabilisation was greatly reduced and steric stabilisation was insuffi-
cient, which led to NP aggregation.
It should be noted that while the benefits of PEGylation are frequently described, 
others have reported that PEGylated particles can elicit PEG-specific immunoglobu-
lin M (IgM), which induces rapid elimination and liver uptake upon repeated doses 
of PEG-coated NPs. This has come to be known as the ‘accelerated blood clearance’ 
phenomenon (Fang et al. 2011; Ishida and Kiwada 2008).
Overall, while many reports describe the functionalisation of silica NPs with bio-
molecules as facile, it is in fact non-trivial and researchers need to carefully consider 
the bioconjugation chemistries used for attachment as it can affect biomolecule ori-
entation on the NP surface (Saha et al. 2014; Jeong et al. 2017) and overall colloidal 
stability of functionalised NPs (Moore et al. 2015). It is therefore appropriate to eval-
uate bioconjugation strategies based on the biological performance of the resultant 
biofunctionalised NP. In doing so, the ‘active surface’ of the NP (i.e. the portion of 
the NP surface containing biomolecules capable to target recognition) can be elu-
cidated and the bioconjugation strategy effectively scrutinised (Moore et  al. 2015; 
Alric et  al. 2016). For example, Herda et  al. (2017) grafted antibody fragments to 
PEG-coated silica NPs and showed that only 3.5% of the randomly bound biomol-
ecules exhibited favourable orientation for antigen recognition.
Extensive and informative reviews of strategies for bioconjugation can be found 
elsewhere and such focussed reading is beyond the scope of this more general review 
(Biju 2014; Sapsford et al. 2013). However, it should be acknowledged that ‘Biocon-
jugate Techniques’ by Hermanson (2013) is the cornerstone and general reference 
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point in the field of bioconjugation. Figure  5 shows popular strategies of NP–bio-
molecule conjugation (Biju 2014). Indeed, it should also be noted that in the case of 
in vivo drug delivery the merits of using of NPs functionalised with targeting moie-
ties remains a matter of debate (Cheng et al. 2012). The development of a NP with 
functionally active biomolecules on the surface has become more challenging than 
expected as the scientists working in the field encountered unforeseen challenges. In 
particular, the targeting molecule, such as an antibody or a ligand, must be function-
alise in an optimal way to ensure that the binding site are available for binding and 
that they are not linked directly to the NP surface, but also that the targeting efficacy 
remains high also when the NP are exposed to a complex biological milieu (Nich-
ols and Bae 2014; Salvati et al. 2013). The choice of a linker or a space between the 
NP and the biomolecule can affect the NP behaviour and targeting properties as the 
choice of the linker and the left can affect the ligand-binding properties of the func-
tionalised nanomaterials (Hristov et  al. 2015b). Despite the technical challenges, 
there is the need of an orthogonal set of methods that can be applied to characterise 
the newly synthesised nanomaterials but also to test whether the active ligand is bio-
logically accessible and prone to interaction with the targeted molecule.
Applications
Immunoassays and biosensors
To date, the trusted immunoassay format for disease diagnosis in clinical setting is the 
enzyme-linked immunosorbent assay (ELISA) and is workhorse of the medical industry 
(Chatziharalambous et al. 2016; Tighe et al. 2015). However, due to emergence of NPs 
Fig. 5 Bioconjugation of biomolecules to silica nanoparticles. A variety of strategies can be employed to 
attach different biomolecules to silica NPs (adapted from Biju (2014))
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in biological research over the past two decades, researchers have focussed on exploit-
ing the physicochemical properties afforded by these nanomaterials in order to achieve 
better signal-to-noise ratios, lower limits of detection, better sensitivity and faster test-
ing times afforded by classical immunoanalytical methods (Farka et  al. 2017). Indeed, 
the most successful example of these efforts is the gold NP-based pregnancy test for the 
detection of human chorionic gonadotropin in urine in less than 10 min (Gubala et al. 
2012).
Variations to ELISA have been described using silica NPs whereby enzymes and tar-
geting antibodies are co-immobilised on silica NPs. For example, Wu et  al. (2009) 
attached horseradish peroxidase (HRP) and α-fetoprotein antibodies on the surface 
of silica NPs and utilised the enzyme for signal transduction. Ke et al. also used dual-
functional silica NPs instead of traditionally used enzyme-labelled antibodies as reporter 
molecules. Amine-coated silica NPs were firstly functionalised with oxidised HRP via 
Schiff base chemistry and investigations into how the spacer length of the amino silane 
(i.e. the number of atoms between the NP surface and the reactive  NH2) used during 
post-coating influenced the enzyme’s binding were carried out. Three aminoalkoxysi-
lanes of different space lengths (4, 7 or 10 atoms) were chosen and it was shown that the 
longest spacer bound the most HRP to the NP surface, which was attributed to a reduc-
tion in steric hindrance and easier access of the enzyme to the reactive site. Residual 
reactive amines on the NP surface were then reacted with oxidised dextran and the car-
bohydrate then served as a crosslinker for antibody attachment for the detection of hep-
atitis B surface antigen, with a detection limit 3 times lower than a commercial ELISA 
being reported (Ke et al. 2010).
Parallel approaches to ELISA using dye-labelled antibodies as probes that facilitate flu-
orescence-based assays are also common and are known as fluorescence-linked immu-
nosorbent immunoassays (FLISA). However, these common organic dye labels are often 
prone to photobleaching (Gao et  al. 2005) and when bound to antibodies the protein 
itself can induce chromophore quenching (Chen et  al. 2010). The limitations of these 
probes have therefore led to the development of optically superior ‘second generation’ 
labels based on NPs such as quantum dots and dye-doped silica (Montón et  al. 2009, 
2012). Silica is particularly attractive due to its predictable and adaptable chemistry, and 
has led to derivatives of a number of commonly used organic dyes [such as fluorescein 
(Moore et al. 2017; Nooney et al. 2012), rhodamine (Dhir and Datta 2016) and cyanine 
(Nooney et al. 2015)] can be covalently bound inside the particle core or on the particle 
surface.
Rusling and co-workers used Ru(bpy)-doped silica NPs, prepared by the reverse micro-
emulsion method as labels in an electrochemoluminescent sensor for the detection of 
prostate-specific antigen (Sardesai et  al. 2009). The NPs were labelled with secondary 
antibodies in a sandwich assay format, with the oxidation of Ru(bpy) used to generate 
luminescence. This work has since been developed into an automated microfluidic array 
for the detection of four different prostate cancer biomarker proteins (Kadimisetty et al. 
2015). Ruthenium-doped NPs have also been used as fluorescent labels in a microarray 
format for the detection of interleukin-6 (IL-6), a cytokine secreted by T-cells and mac-
rophages during inflammation (Wu et  al. 2008a). Capture antibodies bound IL-6 and 
secondary anti-IL6-coated NPs were used as fluorescent reporters.
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Producing fluorescent silica NPs is not limited to the use of traditional organic dyes. 
Wu et al. doped fluorescent carbon nanodots into silica NPs using a reverse microemul-
sion approach, and used these carbon-dot@silica NPs as optical reporter probes for the 
detection of α-fetoprotein (AFP). The 45 nm NPs were functionalised with anti-AFP and 
were capable of capturing AFP in solution. FITC-labelled antibodies were then employed 
to sandwich AFP on the NP surface. The ratiometric signal between the carbon dots 
and FITC was used for signal transduction across a linear range of 0.317–35 μg/dL (Wu 
et al. 2016). The doping of europium into silica NPs has also been reported (Tagaya et al. 
2011) and has been shown to be capable of facilitating HIV p24 antigen detection in 
clinical samples (Chunduri et al. 2017).
The use of broad spectrum antibiotics has lead to the rise of multi drug resistant bacte-
ria and has meant DDSNs are also being used in assays for improved bacterial detection 
and identification. This is undoubtedly pertinent as multidrug resistant bacteria have 
arisen due to the Li and Xu used FITC-doped silica NPs in a sandwich assay format for 
the detection of Shigella flexneri, a bacillary dysentery endemic in countries like China, 
Bangladesh, Pakistan and Indonesia (Li and Xu 2009). Sun and co-workers (2015) have 
demonstrated the capability of detecting Salmonella pullorum using 45 nm silica NPs 
doped with C.I. Reactive Blue 21. This work was later extended to detect Salmonella pul-
lorum and Salmonella gallinarum in powdered milk samples, with a total assay time of 
1 h (Sun et al. 2016). An aggregation-based assay was demonstrated by Jayawardana and 
co-workers (2015) for the detection of the model bacteria Mycobacterium smegmatis. 
Japanese company Furukawa Electric has used commercialised a lateral flow assay incor-
porating fluorescent silica NPs, called Quartz Dots (290 nm) for the detection of differ-
ent infectious microorganisms (Toriyama et al. 2015).
The current challenge for the development of Immunoassays and biosensors applica-
tions is to achieve reliable and stable nonoprobes that will allow good batch-to-batch 
reproducibility and optimal response in the fabricated device. Immunoassay research 
is dominated by gold nanoparticles (Hildebrandt and Tagit 2018), and other classes 
of nanomaterials like magnetic particles, photonic crystals and carbon dots are also 
increasingly used (Banerjee and Jaiswal 2018). However, DDSNs continue to be a highly 
useful probe due to their ability to be synthesised on large scales, their straightforward 
functionalisation and ability to be loaded with different fluorophores.
Bioimaging
In vitro
In the context of this review, in vitro bioimaging typically involves the incubation of NPs 
with cells grown as a 2D culture and probing the subsequent NP–cell interactions by 
using optical methods. For DDSNs, fluorescence-based techniques like confocal micros-
copy and flow cytometry are routinely used to assess NP localisation in the cellular envi-
ronment and/or the presence of specific extra/intracellular analytes. In vitro imaging can 
therefore provide insightful information about, for example, changes in intracellular pH 
or whether DDSNs functionalised with target moieties specifically recognise extracel-
lular receptors.
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The overexpression of folate receptor allows for cell proliferation through the uptake 
of folic acid, which promotes DNA synthesis and cell division (Boogerd et  al. 2016) 
and recent findings have shown that folate receptors to be upregulated in several solid 
tumours. Therefore coating DDSNs with folic acid (folate) has become an attractive 
route to detect cancerous cells overexpressing folate receptor from non-cancerous cells 
for theranostic purposes. For example, Wang et al. developed folate-functionalised dye-
loaded silica NPs for two-photon imaging and labelling of Hela cells in vitro. These cells 
over express folate receptor and specifically uptakes the folate-functionalised NPs. NP 
uptake was reduced when free folic acid was added to the cell culture media and indi-
cated folate–receptor interactions required to enhance uptake. MG63 cells, which have 
been shown to express low levels for folate receptor (Ross et al. 1994), were also shown 
to exhibit minimal uptake (Wang et al. 2010). Yang et al. (2011) also used folate-func-
tionalised FITC-loaded silica NPs to target folate receptor-positive KB cells and sug-
gested that NP endocytosis was likely clathrin-mediated. Santra et  al. (2005) reported 
the labelling of human squamous cancer cells (SCC-9) using fluorescein-loaded silica 
NPs. The use of confocal microscopy then showed that SCC-9 cells were labelled with 
folate-coated DDNPs and attributed the results to specific folate receptor targeting of 
the cell surface. However, Ross et al. (1994) have shown that folate receptor expression 
on SSC-9 cells is in fact low, and highlights how greater experimental evidence proving 
high receptor expression on cell surfaces is needed to confidently claim targeting is due 
to specific NP–cell interactions.
Epithelial cell adhesion molecule (EpCAM) is another extracellular receptor that 
researchers have identified as having a potential role in ontogenesis, and has been tar-
geted by functionalised DDSNs. O’Connell and co-workers (2017) used anti-EpCAM-
functionalised Cy5-doped silica NPs to label and image MCF-7 cells. The 40  nm NPs 
were first coated with PEG and then sensitised with anti-EpCAM to facilitate EpCAM 
targeting on the MCF-7 cell surface. Using confocal microscopy and flow cytometry, the 
NPs selectively labelled MCF-7 cells and exhibited no specific binding towards EpCAM-
negative HeLa cells. MCF-7 cells were considered a model for circulating tumour cells 
(CTCs), which also overexpress EpCAM. However, the potential of using such DDSNs 
for labelling, identifying and quantifying CTCs in patient samples is very challenging as 
there are only few CTCs per billion of blood cells (Shen et  al. 2017). The use of anti-
EpCAM as a targeting biomolecule was also shown by Treerattrakoon et al. (2017) when 
Cy5-doped silica NPs coated with the monoclonal antibody was used to localise the col-
loids in HT-29 colorectal tumours.
The adaptable chemistry of silica NPs and possibility to use the nanomaterials as a 
scaffold have also led to the generation of complex multimodal ‘core–satellite’ NPs to 
increase overall NP functionality. For example, Lee et  al. (2006) generated dual-mode 
NPs by attaching iron oxide NPs to the surface of rhodamine-doped silica NPs and ena-
bled MRI and fluorescence imaging of neuroblastoma cells. Cao et  al. reported core–
satellite use of DDSNs coated with gold NPs for bioimaging. The negatively charged 
citrate-stabilised gold NPs were electrostatically bound to the positively charged 
amine-functionalised silica NP surface. The resultant core–satellite NPs were then 
functionalised with aptamers for the specific recognition and imaging of MCF-7 can-
cer cells in  vitro (Cao et  al. 2011). However, while the capacity to form core–satellite 
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nanoconstructs was clearly demonstrated, the authors only used the gold NPs as a func-
tional surface upon which to attach thiolated aptamers and cellular imaging was facili-
tated by the Rubpy-doped silica NPs. Wu et  al. (2017) described a thermo-responsive 
plasmonic core–satellite nanoassembly and employed gold NP satellites anchored to 
silica NPs via heat sensitive poly(N-isopropylacrylamide) for biophotonics and biosens-
ing applications.
Intracellular sensing and imaging has also been reported with DDSNs and can be per-
formed using two different luminescent probes for ratiometric fluorescent sensing; one 
probe is typically sensitive to analyte while the second is used as a reference (Zou et al. 
2016). For example, McDonagh and co-workers used 70  nm Stöber-synthesised silica 
NPs for intracellular pH sensing. The NP core was doped with Texas Red (reference dye) 
while the NP exterior was functionalised with pH-sensitive fluorescein, and demon-
strated the capacity for pH monitoring in human embryonic kidney cell line upon the 
transition from acidic to basic environment (Korzeniowska et al. 2014).
Intracellular microRNA sensing was demonstrated by Li and co-workers (2014) 
in vitro in MCF-7 cells using DDSNs as delivery vehicles for crossing the cellular mem-
brane. The surface of the coumarin-loaded NPs was functionalised with targeting 
aptamers and a fluorescence-based molecular beacon. The molecular beacon consisted 
of double stranded DNA: one strand labelled with a fluorescent probe (fluorescein amid-
ite, FAM) and the other was labelled with a quencher (dimethylaminophenylazobenzoic 
acid, DABCYL). The aptamers allowed for specific recognition of the cancer cells and 
subsequent NP uptake. Once inside the cells the molecular beacon then preferentially 
bound miRNA-21, which caused the displacement of the DABCYL-functionalised sin-
gle strand, and allowed for FAM to fluoresce to indicate the presence of miRNA-21. 
This strategy was possibly inspired by the use of molecular beacons and gold NPs first 
described by Mirkin (Seferos et al. 2007).
In vivo and ex vivo
Fluorescence in  vivo imaging typically uses the tissue-penetrable near infrared (NIR) 
light for image generation. For example, Belfield and co-workers employed folate-func-
tionalised silica NPs for in  vivo (one-photon) and ex  vivo (two-photon) fluorescence 
imaging in HeLa xenograft model in mice. A pyran-derivative capable of two-photon 
absorption and aggregation-enhanced NIR emission was encapsulated into silica NPs 
and allowed for high loading of the chromophore inside the colloids, with tumour pen-
etration depths of 350 µm (Wang et al. 2011b). Biffi et al. developed PEGylated silica NPs 
(10 nm) loaded with Cy5.5 and Cy7 in a 2-to-1 ratio for flow cytometry and in vivo imag-
ing applications. In healthy mice, NPs accumulated mostly in the liver and intestine after 
24 h, with a negligible amount found in the spleen or brain. After 96 h, a reduction in 
NP accumulation throughout the mouse was observed, but the largest remaining quan-
tity was found in the liver. No fluorescence could be detected in urine as the NPs were 
greater than the 8 nm renal glomerular filters. In lymphoma xenograft tumours, the NPs 
were detected in tumours 24 h post-injection and subsequently cleared after 48 h (Biffi 
et al. 2014). In spite of these interesting results, the authors did not quantify the percent-
age of NPs that reached the tumour site and only report ‘significant accumulation’. This 
lack of quantification is widespread in the literature and is also relevant to intravenously 
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administered NPs that are intended for cancer treatment. In fact, it has been reported 
that only around 0.7% of administered NPs reach tumours (Wilhelm et  al. 2016) and 
highlights the reality that efficacious NP-based imaging and drug delivery agents are 
extremely challenging to engineer.
Indocyanine green (ICG) is an injectable FDA-approved NIR dye used in the clinic 
that is considered non-toxic but suffers from a range of issues that has hindered its use 
in fields like image-guided surgery: poor circulation half-life (Kitai et al. 2005), tendency 
to bind commonly found serum proteins (Desmettre et al. 2000; Mordon et al. 1998) and 
low quantum yield in water and blood (Hong et al. 2016). To this end, silica NP formula-
tions have been reported as a way to improve the stability of ICG. One challenge associ-
ated with ICG encapsulation inside silica NPs is the inherent negative charge of the dye, 
which makes it difficult to entrap within the negatively charged particle matrix. Quan 
et al. addressed this issue by complexing positively charged polyethylene imine with ICG 
and subsequently doping them into the silica matrix. The ICG-doped silica NPs were 
then capable of being detected at a 2-cm depth in porcine muscle (Quan et al. 2012).
The biodistribution and clearance of ORMOSILs was performed in healthy, non-
tumour bearing mice (Kumar et  al. 2010). The NIR dye DY776 was covalently incor-
porated inside the ORMOSIL matrix, with the resultant dye-doped NPs then being 
functionalised with PEG. The NP surface was subsequently radiolabelled with 
iodine-124 and the resultant 20–25  nm NPs offered dual-mode in  vivo imaging capa-
bility. The ORMOSILs largely accumulated in the liver and spleen after 24 h and great-
est fluorescent signal 72  h post-injection came from the skin, which then gradually 
decreased until the end of the study where only 3% of the original fluorescent signal was 
distributed in the stomach and intestine (360 h). Interestingly, this skin signal was later 
adjudged to have come from the DY776 released via NP dissolution. Almost 100% of the 
injected ORMOSILs were eventually excreted via hepatobiliary transport, which is not 
the desired route as the reticuloendothelial system exhibits longer retention compared 
to renal excretion. Nonetheless, tissue sections of a number of organs indicated no tox-
icity upon NP exposure and the physical and neurological wellbeing of the mice after 
1 month indicated no changes in behaviour or physical features.
The most impactful results for DDSNs in in vivo imaging have been reported by the 
Wiesner group and their translation to human clinical trials for metastatic melanoma 
cancer imaging (Ma et al. 2015, 2016; Phillips et al. 2014). The surface chemistry of the 
Cy5-loaded sub-10  nm NPs employs PEG terminated with 124I-labelled cyclic-RGDY 
peptide (Fig.  6) (Phillips et  al. 2014). The arginine–glycine–aspartic acid tripeptide 
(RGD) is known to bind to ανβ3 integrin receptor (ABIR), which is overexpressed in 
some cancer cell lines. The NPs therefore have dual imaging capability via Cy5 fluo-
rescence and 124I positron emission tomography (PET), and a functionalised PEG layer 
that allows for integrin targeting via cRGDY peptide. Under Investigational New Drug 
status from the FDA, initial human studies (Trial number NCT01266096) have shown 
that the C-dots were well-tolerated by patients, were renally excreted (Fig. 6a, b) and 
could even accumulate in tumour sites (Fig. 6c–e). However, as the number of patients 
was limited to 5, it is thought that a larger participant number is needed to confirm 
the lack of toxicity and tumour targeting, but the results suggest these C-dots could 
be a promising cancer imaging agent in the future. Another study aimed for head and 
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neck cancer imaging is also underway using these ultrasmall DDSNs (Trial number 
NCT02106598).
Here, the NPs aim to be used for real-time imaging agents for sentinel lymph node map-
ping during surgeries, thus potentially allowing surgeons to detected diseased nodes with a 
hand-held camera. Targeting peptides on the NP surface aim to specifically recognise can-
cerous tissue such that surgeons can avoid the resection of healthy lymph node. This strat-
egy aims to improve upon current sentinel lymph node mapping approaches using dyes that 
insufficiently accumulate in nodes and exhibit short retention times (Hameed et al. 2019).
Others have also reported the use of peptide-functionalised DDSNs. For example, Wu 
et al. (2008b) used RGD-coated fluorescent silica NPs to target and image ABIR-positive 
MDA-MD-231 breast cancer in vitro and ex vivo. In their mouse xenograft model, the 
peptide-labelled NPs achieved maximal labelling capacity 1-h post-injection. However, 
after 48 h, minimal fluorescence from tumours was observed and suggested the need to 
improve NP circulation times.
Functionalising silica NPs with the well-known cell penetrating peptide TAT 
(trans-activating transcriptional activator), which is derived from HIV, has also 
proven useful as an efficient way of labelling cells and transporting cargo across cell 
membranes. Santra et al. (2004), for example, demonstrated how 70 nm FITC-loaded 
silica NPs conjugated with TAT peptide could successfully be used to image A549 
lung carcinoma cells in vitro and brain blood vessels in vivo, with the authors claim-
ing to cross the blood brain barrier without compromising its integrity.
Overall, silica NPs have been widely used for in vitro and in vivo imaging due to 
the multiple synthetic approaches to doped the material with fluorescent dye but 
Fig. 6 Bioimaging clinical trials in humans using C-dots. a, b Whole-body distribution and PK of 124I-cRGDY–
PEG–C dots. a Maximum intensity projection PET images 2, 24, and 72 h after IV injection of 124I-cRGDY–
PEG–C dots demonstrated probe activity in the bladder (*), heart (yellow arrow), and bowel (white 
arrowhead). b Decay-corrected percent injected dose per gramme (%ID/g) of urine and plasma collected 
around 30 min, 4 h, 24 h, and 72 h after injection determined by gamma counting. Regions of interest were 
drawn on major organs for each patient’s PET scans to derive standardised uptake values and %ID/g (n = 5 
patients). Plasma clearance half-times, t1/2, 1 and t1/2, 2 were attributed to renal and hepatobiliary clearance, 
respectively. c Magnetic resonance, MR, axial and sagittal images of the brain showing a subcentimeter cystic 
focus (arrows) in the pituitary gland. d MRI–PET images showing localisation of the C-dots (red spot) in the 
lesion site. e PET–CT images showing the same localisation (adapted from Phillips et al. (2014))
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also to adapt the particle synthesis to a given requirement. One important consider-
ation in the use of DDSNs in bioimaging is their capacity to be degraded. After expo-
sure to biological fluid silica NPs can be etched and hollowed, consequently causing 
a release of encapsulated material. While this can be advantageous for controlled 
drug release applications, for imaging it means released chromophores can cause 
background noise and erroneous conclusion on the NP intracellular trafficking and 
biodistribution. While this issue was partially addressed by Mahon et  al. (2012b) 
when they adapted their NP synthesis protocols to increase particle stability in vitro, 
further studies are needed to test particle stability in vivo.
The ability to control DDSN synthesis is another attractive feature associated with 
using dye-doped silica in in vivo imaging. This is particularly evident for the case of 
C-dots being used in human trials where monodisperse sub-10 nm NPs are needed 
for renal clearance. Ultrasmall Silica NPs (AGuIX NPs, ~ 5 nm) are also being used 
(as radiosensitisers) in human trials and it is striking that a similarity between both 
these two silica NP platforms is their ultrasmall size (Lux et  al. 2019). Consider-
ing both have reached human trial stage, it suggests that small silica NPs may be 
required for translation from the bench to bedside.
Disease treatment
Cancer therapy
Drug delivery applications using silica NPs for the delivery of therapeutic agents to dis-
ease sites have largely focussed on cancer treatment and transportation of colloids to 
tumour sites via the blood. Strategies are typically founded on the idea of exploiting the 
EPR effect; an effect only known to be observed in cancerous tissue (Peer et al. 2007). 
Tumours are generally reproduced in vivo using xenograft or orthotopic murine models 
and therefore allows for NP circulation, tumour accumulation and drug delivery to be 
studied. However, it should be noted that it can be challenging to realistically replicate 
human-like tumour environments using these models (Nichols and Bae 2014) but mice 
studies remain useful for early stage in vivo experimentation.
Traditional chemotherapeutics have been shown to be capable of being encapsulated 
inside silica NPs and used for cancer treatment. Roy et al., for example, prepared doxo-
rubicin-loaded ORMOSILs of 30, 50 and 80 nm diameter using vinyltriethoxysilane as 
a NP precursor via oil-in-water microemulsion. The 50 nm NPs were shown to exhibit 
optimal drug release over a 2-week period to pancreatic MiaPaCa-2 cells, whilst unload 
NPs were deemed non-toxic (Roy et al. 2014).
Gene delivery is another method of cancer therapy. For example, Tivnan and Orr et al. 
(2012) reported how NIR664-doped silica NPs loaded with microRNA could specifically 
target and kill neuroblastoma tumours in vivo using a murine xenograft model (Fig. 7). 
The NP core was loaded with miR-34a, a microRNA that targets genes associated with 
cell proliferation and apoptosis, and the particle surface was sensitised with an antibody 
that specifically binds to disialoganglioside, a glycolipid that is expressed in high lev-
els on the surfaces of neuroblastoma cells. The particles also showed minimal uptake 
in organs and a high degree of biocompatibility. NP dissolution via hydrolysis was pro-
posed as the release mechanism of miRNA from the particles.
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Ye et  al. also demonstrated the ability to deliver genetic material in in  vitro and 
in vivo experiments when they used peptides for synergistic cell penetration and endo-
somal escape of gelatin-coated silica NPs. The combined presence of TAT peptide and 
fusogenic peptide HA2 on the NP exterior allowed for the successful transfection of 
luciferase DNA plasmid pGL3 (Ye et al. 2012). This work was later extended when gel-
atin-coated silica NPs were functionalised with tumour targeting aptamers and PEG for 
extended circulation time (Zhao et al. 2016).
The ultrasmall DDSNs developed by the Wiesner group were also studied for their 
drug delivery capabilities. For example, Yoo et al. reported the design of NP–drug con-
jugates. The authors reported the synthesis of enzyme-cleavable peptide–drug con-
structs, and the subsequent conjugation of the constructs to the surface of 6–7 nm silica 
NPs. The presence of proteases led to the cleavage of the linker–drug constructs, and, 
in vitro, could reduce phosphorylated epidermal growth factor receptor (EGFR) levels 
in human tumour-derived H1650 cells (Yoo et al. 2015). The same ultrasmall silica NPs 
have also been shown to be capable of inducing ferroptosis in nutrient-depleted cancer 
cells (Dixon et al. 2012).
Ferroptosis is a form of regulated cell-death mechanism induced by specific changes 
in the intracellular environment, notably severe lipid peroxidation which relies on ROS 
generation and iron availability (Galluzzi et al. 2018).
Fig. 7 Delivering therapeutic microRNA with silica nanoparticles for cancer therapy. Anti-disialoganglioside 
 (GD2) sensitised DDSNs were used to treat neuroblastoma in mouse xenograft model. The NPs contained 
a NIR dye as a contrast reagent and were loaded with therapeutic miRNA34-a. a (left) Antibody-coated 
NPs containing a scrambled RNA sequence or (right) miRNA34-a were injected into GD2-positive 
NB1691 tumours and only those containing miRNA34-a reduced tumour size, b and was also the case for 
GD2-positive SK-N-AS tumours. c The NPs only tended to accumulate in the tumour tissue and avoided 
retention in organs like the liver and spleen and d biodistribution was quantified by fluorescence (adapted 
from Tivnan et al. (2012))
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Radiotherapy using NPs is an increasingly studied field in cancer theranostics and 
gold NPs have featured prominently in research (Jain et  al. 2011; McMahon et  al. 
2011; Hainfeld et al. 2004; Subiel et al. 2016). However, one class of silica NPs known 
as AGuIX NPs have shown promising results to date and have demonstrated their effi-
cacy in a variety of cancer models [e.g. pancreatic (Detappe et al. 2016), lung (Dufort 
et al. 2014), bone (Miot-Noirault et al. 2014)]. This has led to a human-based clinical 
trial (NANO-RAD, Trial number NCT0282045) focusing on the radiosensitisation of 
brain metastases that originated from lung, melanoma, colon and breast cancers. The 
AGuIX NPs demonstrated accumulation in brain tumour sites that were previously 
detected by conventional  T1 MRI contrast reagents, as well as a lack of nanomate-
rial detected in healthy brain tissue. NPs accumulated in tumour sites despite passive 
targeting and this was attributed to the ability of the nanomaterial to cross the blood–
brain barrier and exploit the EPR effect. Another clinic trial using AGuIX NPs (Nano-
COL, Trial number NCT03308604) is also underway and aims to evaluate the human 
tolerability and safety of increasing doses of AGuIX NPs used in combination with 
brachytherapy therapy and cisplatin treatment in locally advanced cervical cancers. 
Similarly to the Cornell dots developed by Weisner et al. (Phillips et al. 2014), the use 
of ultrasmall NPs is employed as a way of maximising renal clearance of intravenously 
administered particles that do not localise in tumour sites.
Photodynamic therapy (PDT) and photothermal therapy (PTT) using NPs are forms 
of physically based treatment gaining increased interest from scientists as a way of over-
coming chemotherapy-resistant cancers and typically rely on NIR excitation sources as 
it can penetrate millimetres into the skin (Henderson and Morries 2015; Ash et al. 2017). 
PDT uses a photosensitiser which, upon exposure to light, generates singlet oxygen (1O2) 
and acts as a reactive species that can ultimately cause cell death. Benachour et al. used 
gadolinium-loaded silica NPs and a chlorin photosensitiser to facilitate dual-functional 
MRI and PDT. The NPs were functionalised with peptides that allowed for retention of 
the NPs in intracranial tumour sites in a rat xenograft model, thereby facilitating brain 
imaging (Benachour et al. 2012). Ohulchanskyy et al. (2007) modified an iodine-exhibit-
ing pyropheophorbide derivative to allow for the photosensitiser to be covalently linked 
inside the silica matrix and then used the colloids to kill Colon-26 cells. In another 
study, an aggregated fluorescent dye capable of two-photon excitation was encapsulated 
inside the matrix of the 30 nm ORMOSIL NPs and used as a FRET donor for sensitising 
a co-encapsulated 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide, HPPH. Indirectly 
exciting HPPH via energy transfer from the aggregated dyes generated singlet oxygen 
intracellularly and led to cancer cell toxicity in vitro (Kim et al. 2007).
Singlet oxygen generation using photosensitisers has also been shown to be more effi-
cient in the presence of heavy atoms, an effect known as the heavy atom effect. Here the 
photophysical and biological properties of photosensitisers can be optimised by incor-
poration functional group containing heavy atom such as bromine (Gorman et al. 2004). 
The number and the localisation of bromine substituents can tune the efficiency of the 
electronic transition from a singlet to a triplet state, leading to more effective energy 
transfer from the excited derivative onto oxygen. Zheng exploited this by synthesising 
a silylated boron-dipyrromethene (BODIPY) derivative containing iodine atoms and 
subsequently covalently bound this probe into silica NPs (Wang et  al. 2015). The NPs 
Page 25 of 43Gubala et al. Cancer Nano            (2020) 11:1 
were incubated with HeLa, MCF-7 and SKBR-3 cells and showed significant cytotoxicity 
upon laser exposure compared to NPs doped with BOPIDY without iodine. The authors 
also suggested replacing the heavy metal with its radioactive form to allow for future 
PET imaging.
PTT utilises photosensitisers that convert the energy of incident photons to heat. 
Hyperthermia, the heating of tissue to 41–47  °C over tens of minutes (Hayashi et  al. 
2014), causes irreversible cell membrane damage and protein denaturation that even-
tually leads to cell death. This is particularly useful in hypoxic tissues as oxygen is not 
required. Shan et al. (2013) showed the PTT capacity of NIR CyTE-777 coated silica NPs 
to be used as a PTT agent. In vitro experiments demonstrated a 42% reduction in mac-
rophage viability under 780 nm excitation. However, the authors stated that their nano-
composite exhibited lower heating efficiency compared to gold nanorods typically used 
in PTT.
Synergistic dual PTT and PDT has also been reported using 42 nm porphyrin-loaded 
silica NPs in vivo (Hayashi et al. 2014). The crosslinking of iodopropyltrimethoxysilane 
in the NP matrix exploited the heavy atom effect to promote more efficient generation of 
1O2 and heat. Importantly, the study deviated from laser excitation sources and utilised 
LEDs for photosensitiser illumination, which reduces the degradation of the sensitiser 
over extended excitation periods and is more practical for clinical settings.
Non‑cancerous applications
The blood–brain barrier (BBB) is a highly cooperative system composed of endothelial 
cells, extracellular matrix, pericytes, neurons, astrocytes and a variety of enzymes, recep-
tors, transporters and efflux pumps (Barbu et al. 2009). It is therefore highly challenging 
to deliver therapeutic agents to the brain and different physical and chemical strategies 
for BBB disruption have emerged (Zhang et al. 2016). However, these strategies are not 
without risk as BBB disruption can be can linked to strokes (Sandoval and Witt 2008) 
and central nervous system diseases (Sweeney et al. 2018). To this end, improved strat-
egies based on NP systems that maintain maximal barrier integrity are required, and 
because silica is described as a promising drug delivery platform there have been reports 
of BBB studies with the dye-loaded nanomaterials.
A systematic study by Song et al. (2017) using Ru(bpy)-doped silica NPs produced via 
the reverse microemulsion method were used to investigate particle transcytosis in vitro 
BBB model. The NPs (25 nm, 50 nm, 100 nm) were PEGylated and further functional-
ised with lactoferrin, a cationic iron-binding glycoprotein that can bind to the lactoferrin 
receptor present on vascular endothelial cells of the BBB. Without lactoferrin on the NP 
surface less than 5% of particle crossed the BBB, whereas NPs exhibiting the glycoprotein 
were transcytosed in a size-dependent manner. Reducing NP diameter led to increasing 
transport efficiency with 25  nm, 50  nm, 100  nm quantified to have 21.3%, 11.6% and 
5.8% efficiency, respectively. Importantly the authors also showed that the introduction 
of the NPs into the BBB system did not affect tight junction integrity as low sodium flu-
orescein permeability coefficients were calculated. ORMOSILs were also shown to be 
capable of entering neuronal regions when they were fed to Drosophila (Barandeh et al. 
2012). No effect on organism viability was observed despite the NPs penetrating into the 
brain, neuronal cell body and axonal projections.
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Ku et al. (2010) reported the transcytosis of 80–90 nm PEGylated silica NPs across the 
tightly bound endothelial cells lining the barrier after 1 h in rats, whereas non-PEGylated 
counterparts exhibited no crossing. Transmission electron microscopy (TEM) was used 
to visually investigate brain slices to elucidate their localisation. Particles were found in 
astrocytes and it was also confirmed by confocal microscopy that NPs managed to locate 
in neurons. On the other hand, multiple in vivo studies have shown that NPs are not able 
of crossing the BBB (He et al. 2008) and is fact one of the greatest challenges facing the 
drug delivery community. Discrepancies in experimental outcome can be due to differ-
ent experimental parameters, with a major contributor being the choice of BBB model. 
Models exist for different organisms (fruit flies, zebrafish rodents and humans) and dif-
ferences exist across species. For example, pericytes and astrocytic end feet are more 
prevalent in the human neurovascular unit compared to mouse brains (O’Brown et al. 
2018). BBB in vitro and in vivo models also differ (Stanimirovic et al. 2014). Researcher 
should therefore consider the model chosen and, in addition, the physicochemical char-
acterisation of NPs in biological fluids when analysing BBB studies.
Silica NPs have shown they can also be useful for treating other diseases such as oste-
oporosis. Researchers at Emory University have shown that silica NPs are not totally 
inert and can intrinsically benefit the biological activity of osteoblasts and osteoclasts 
(Beck et al. 2012; Ha et al. 2014; Weitzmann et al. 2015). Silica NPs themselves stimulate 
bone-forming osteoblasts, suppress bone-resorbing osteoclasts and enhance bone min-
eral density in vivo (Beck et al. 2012). Silica NPs therefore could potentially be a novel 
method of treating osteoporosis and advantageous compared to current treatments 
that only target osteoclasts but do not rebuild bone mass (Ha et  al. 2014; Weitzmann 
et al. 2015). Following caveolae-mediated endocytosis of the NPs in osteoblasts, a sig-
nal transduction pathway dependent on ERK1/2 was stimulated. Autophagic proteins 
bound to the NPs were processed when ERK1/2 was stimulated and, following process-
ing, led to autophagosome formation (Ha et al. 2014). This cascade of events was com-
mon for both –OH and PEGylated silica NPs and subsequently led to the activation of 
autophagy, which has been shown to be associated with osteoblast differentiation and 
mineralisation (Liu et al. 2013).
Silica NPs can also be used to facilitate core–shell architectures, where the shell is 
composed of a second nanomaterial (e.g. silica–gold). The plasmonic properties of gold 
can then be used for thermal-based treatments of diseases. For example, Sebashells (pro-
duced by Sebacia) have undergone trials for the treatment of dermatological conditions 
like acne (Fig. 8) (Anselmo and Mitragotri 2015). A thin gold shell around a silica core 
(Fig. 8a) was used to thermally ablate sebaceous glands and the eradication of the acne 
source. The NP formulation is applied topically and an ultrasound source encourages the 
penetration of the NPs deep into the gland (Fig. 8b). NIR light (similar to that used for 
laser hair removal) is used for tissue penetration and is absorbed by the gold shell. The 
gold shell converts the absorbed light into heat energy and results in glandular thermol-
ysis (Fig. 8c). The ultrasound and NIR technologies are similar to tools already approved 
by the FDA and overall the Sebashell treatments appear to have been well-tolerated by 
patients, but further studies will be required to assess NP clearance (Paithankar et  al. 
2015).
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Overall, it is positive to see silica NPs being used in human trials for cancer treatment 
(Lux et al. 2019) and represents a breakthrough in the use of silica NPs in disease ther-
apy. It is interesting that the focus of researchers has been to develop ultrasmall NPs 
that can be cleared through the kidneys as this strategy has been mirrored by the C-dots 
(Phillips et al. 2014) being used in human bioimaging trials. It is therefore clear that silica 
NPs have the potential to become reliable and clinically relevant imaging and therapeu-
tic agents. While these clinical trials have primarily studied the safety and pharmacoki-
netics of their nanomaterials over short time scales (days), the nanomaterials appeared 
to be well-tolerated. The scientific community should therefore follow the progression of 
these trials closely and attempt to establish parallels with these technologies that have so 
far be translatable to humans.
Challenges
The use of NPs in biological applications is continuously growing in popularity, and it is 
therefore important to assess NP interactions with complex biological media to better 
understand the formation of biomolecular coatings on particle surfaces and the resultant 
biological fate of such particles. A deeper knowledge of these interactions will ultimately 
lead to better predict toxicity across a range of exposure routes, e.g. upon inhalation, 
ingestion, injection or via transdermal penetration (Kim et al. 2015). However, the lack 
of standardisation in nanotoxicology experimentation has led to of conflicting reports 
on colloidal silica NP biocompatibility in the literature (as is the case for almost all nano-
materials), and has hence evaluating and summarising the effects NPs have on various 
cells lines and whole organisms is challenging (Gubala et al. 2018a). In addition, it is also 
crucial to consider that there are multiple forms of nano-form silica employed in bioap-
plications and that improved physicochemical characterisation of the NPs is required 
prior to toxicological studies (Gubala et al. 2018b). For example, factors like the choice of 
synthetic route and crystal structure may affect biological responses (Murugadoss et al. 
2017). Researchers must therefore consider silica NPs as a class of nanomaterial with a 
Fig. 8 Silica nanoparticles are regularly used as core materials in core@shell nanomaterials designed for 
biomedical applications. For example, Sebashells are currently undergoing clinical trials for the treatment of 
acne. a Particle architecture consists of a silica core and a gold shell. When excited with near infrared light the 
gold shell heats and ablates sebaceous glands. b Sebashells are applied topically and penetrate sebaceous 
glands through ultrasound stimulation. NIR laser light is then used for gold shell to induce heat production. c 
Such heat treatment can result in deep glandular thermolysis (adapted from Anselmo and Mitragotri (2015))
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number of subtypes (e.g. microporous, mesoporous, food grade), each of which should 
be considered individually and thoroughly physicochemically characterised before bio-
logical testing.
Protein corona
In spite of the efforts made by materials scientists to control and impart specific sur-
face properties to silica NPs, it is now widely accepted that once these nanomaterials 
are introduced into complex biological fluids like serum, blood or urine the surface 
properties of the NP can be dramatically changed. This surface fouling is attributed to 
biomolecule (mainly protein) adsorption around NP surfaces and is referred to as the 
‘protein corona’. There are two layers of this corona that coat NPs; ‘hard’ and ‘soft’ (Fig. 9) 
(Monopoli et  al. 2012). A hard corona is a near-monolayer of biomolecules tightly 
bound, but not irreversibly, to the NP surface. Surrounding this layer is the ‘soft’ corona, 
which is composed of more loosely associated and rapidly exchanging biomolecules. It 
is the hard corona that is believed to provide the environmentally derived identity of a 
given nanomaterial that a cell would actually interact with Li et al. (2010), Mahon et al. 
(2012a). Tenxer et al. (2013) showed that it can take as little as 30 s for a protein corona 
to form on silica NPs, and researchers should begin to regard the corona as defining 
‘the bio-nano interface’ that can cause unpredicted interactions with biological systems 
(Walczyk et al. 2010; Soddu et al. 2019).
For example, Lara et  al. (2017) showed that the epitopes of two major proteins in 
serum, low-density lipoprotein and immunoglobulin G, are presented on the surface of 
silica NPs and can be recognised by their respective receptors. The authors suggested 
Fig. 9 The protein corona, and its manipulation, poses many new challenges and opportunities in 
bionanotechnology. a The strong adsorption of biomolecules to a NP surface in complex media (known as 
the ‘protein corona’ can alter the biological identity of NPs and has recently been described what a cell ‘sees’ 
upon encountering the particle-corona complex. b A number of association/dissociation reactions occur at 
the NP-cell interface. Some biomolecules bind tightly to form a ‘hard’ corona and others loosely surround the 
NP (a ‘soft’ corona) (adapted Monopoli et al. (2012))
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that cells may therefore be ‘mistakenly’ recognising NPs (based on their corona com-
position) as endogenous or exogenous objects, such as lipoproteins or viral infections, 
respectively, and may in turn govern how the NPs are biologically processed and/or 
cleared.
In the case of nanomedicine this presents a challenge as biomolecule-functionalised 
silica NPs are designed for recognising specific cellular receptors can lose their targeting 
capability. In a notable study by Salvati et al. (2013) transferrin-coated silica NPs were 
shown to lose their ability to target transferring-receptors on cancer cells in vitro. The 
loss of targeting capability was observed when the experiments were performed in cell 
culture medium supplemented with serum. Without serum supplementation, no corona 
was formed and transferrin receptor could be recognised by the transferrin-coated NPs. 
Kelly et  al. (2015) extended this work by visually mapping the reduction of antibody-
coated NP functionality upon corona formation using TEM, differential centrifugation 
and other techniques. Researchers must therefore carefully consider the supposed ben-
efits associated with producing biomolecule-functionalised NPs capable of target recog-
nition in vivo and must interpret experimental results with the side effects of the protein 
corona in mind. It has also been shown for silica NPs that the physicochemical proper-
ties and biomolecular composition of the corona significantly evolves when protein con-
centrations change from those used in in vitro studies to those found in vivo, and holds 
deep implications in studying biodistribution, toxicity and a host of biological responses 
to silica NPs (Monopoli et al. 2011).
It has been hypothesised that precise corona modifications could lead to a greater 
understanding of how the different biomolecules coating the NPs influence cellu-
lar interactions. For example, around 50% of all human proteins contain glycan units 
(Bohne-Lang and von der Lieth 2005) that can influence protein immunogenicity, traf-
ficking, stability and folding (Paszek et  al. 2014; Moremen et  al. 2012) and Wan et  al. 
(2015) demonstrated how their presence/absence in the protein coronas can modulate 
macrophage interactions. Compared to fully glycosylated coronas, the removal of the 
glycans led to enhanced NP adhesion and uptake in THP-1 macrophages, which ulti-
mately led to an increase in pro-inflammatory cytokines by the cells.
Another study by Monopoli and co-workers developed an analytical method for modi-
fying a human plasma-derived protein corona on silica NPs through the use of sur-
factants. Cholamidopropyldimethylammonio propanesulfonate (CHAPS), a zwitterionic 
surfactant, could selectively extract apolipoprotein AI (ApoAI) from the hard corona 
formed on SiNPs without affecting particle size. Silica NPs with ApoAI-depleted coro-
nas did not aggregate upon the introduction of anti-ApoAI and suggested the possibility 
of engineering the hard corona to reduce specific biological interactions. On the other 
hand, the introduction of anti-ApoAI caused silica NPs untreated with CHAPS to aggre-
gate in the presence of ApoAI and suggested the presentation of binding epitopes in the 
outer layer of the hard corona. The authors also commented that removing specific pro-
teins would subsequently result in new protein binding sites to be exposed on the corona 
surface and would possibly lead to different interactions of the NP with cellular machin-
eries (Maiolo et al. 2014).
Further studies are needed to fully understand the influence of corona in receptor acti-
vation, signal transduction and biodistribution of NPs, but it is encouraging to see how 
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the scientific community is attempting to answer fundamental questions posed by the 
use of NPs in biological environments. Improvements in the ability to manipulate the 
corona will undoubtedly lead to greater understanding of NP interactions with cellular 
machinery, and it has been predicted that it may eventually be possible to produce more 
favourable cell targeting with NPs to result in more efficacious disease treatment (Ke 
et al. 2017; Mahon et al. 2012a).
Despite the numerous research papers in the field, it is clear that multiple parameters 
affect the biomolecular corona formation, such the temperature of the incubation, the 
time, the total mass of the biomolecules in the exposing media type, along with the ana-
lytical techniques to isolate and to characterise the corona complexes. Such techniques 
either directly or indirectly measure corona formed on NPs and the use of complemen-
tary analytical methods is advised (Carrillo-Carrion et al. 2017). A recently publication 
has highlighted the characterisation challenges associated with protein corona investiga-
tions and a minimal information about nanomaterial-biocorona experiments has been 
suggested (Chetwynd et al. 2019).
The importance and relevance of the corona has begun to attract attention in several 
regulatory documents, although its characterisation is not a requirement yet. In particu-
lar, the European Food Safety Authority (Hardy et al. 2018), International Life Sciences 
Institute (Cockburn et  al. 2012) and the US Food and Drug Administration (US FDA 
Center for Drug Evaluation and Research 2017) have all highlighted that the corona is 
a factor that has to be taken into consideration in the evaluation of the nanomaterials 
although the community is still investigating the minimal parameters that are required. 
The Scientific Committee on Emerging and Newly Identified Health Risks of the Euro-
pean Commission has also noted, in an opinion on the determination of potential health 
effects of nanomaterials used in medical devices (2015) that “because nanomaterials 
may acquire a new biological identities, i.e. new properties via the adsorption of biomol-
ecules (the bio-corona) onto their surface, it is essential during toxicological studies to 
assess the interaction between these and how these may interact with the physiological 
response of the organism” (European Commission 2015). Overall, it is clear that assess-
ment of the bio-corona on NBMs is important, yet this currently represents a regulatory 
gap in nanomedicine the importance of the bio-corona as a factor that has to be taken 
into consideration in the evaluation of nanomaterials (Halamoda-Kenzaoui et al. 2019).
Toxicity
Food grade synthetic amorphous silica (SAS) is a food additive (E551, silicium dioxide) 
and is used as an anti-caking agent in food products. An informative overview of SAS 
safety by Fruijtier-Pölloth (2016) concluded that, based on current evidence obtained by 
various global regulatory bodies, no significant risk to human health is posed by E551. 
However, SAS is considered to be a different class of material to the colloidal suspen-
sions synthesised by methods outlined earlier in this review. Therefore, SiNP would 
not comply with the specifications established for E551, and would require their own 
application-specific safety and risk assessments. It is therefore crucial to note that col-
loidal silica will not necessarily be non-toxic and safe to use in vivo simply because SAS 
has so far been deemed to be of low risk to human health (Fruijtier-Pölloth 2016). In 
this light, the human clinical trials using DDSNs from the Wiesner group for bioimaging 
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(Phillips et al. 2014; Benezra et al. 2011) will provide important insights into silica NP 
tolerance and should enable a number of new paradigms for this class of nanomaterial to 
be established.
Some reports have described silicon-based materials as naturally biodegradable and 
that they dissolve into silicic acid (a naturally occurring compound) (Park et  al. 2009; 
Kempen et al. 2015). However, assessing the toxicity of colloidal silica NPs remains unre-
solved and is particularly hampered by the lack of agreed experimental protocols. This 
has meant a variety of different experimental parameters have been studied: NP size 
(Kim et al. 2015) and agglomeration-state (Giovannini et al. 2018b; Halamoda-Kenzaoui 
et al. 2017), NP surface chemistry (Hsiao et al. 2019), NP corona composition, (Lee et al. 
2015) particle concentration (Kim et al. 2015) and cell type (Kim et al. 2015). This wide 
variation in experimental conditions has therefore led to a lack of consensus on whether 
colloidal silica can be definitively considered to be toxic (Krug 2014).
The presence of serum in cell culture media used for in vitro studies is now regarded 
as a key experimental parameter as it can influence cellular responses to NP expo-
sure (Francia et al. 2019). Scrutiny of experimental conditions is therefore important 
and, in the case of in vitro experiments conducted in the absence of serum, caution 
should be taken when interpreting NP–cell interactions. For example, viability studies 
in mouse keratinocytes using silica NPs with diameter 30, 48, 118 and 535 nm showed 
decreased cell survival with decreasing size across a dosage range of 10–200 μg/mL 
(Yu et al. 2009). However, NPs were exposure to cells in culture media in the absence 
of serum and results/trends should be interpreted in this context. A different study 
involving human hepatocytes employed silica NPs with diameters of 7, 20 and 50 nm 
at dosages of 20–640 μg/mL. Cells were cultured in the presence of serum and viabil-
ity reduced in the order of 20 > 7 > 50 nm (i.e. no clear size dependence), and was dose 
and exposure-time dependent (Lu et  al. 2011). The ability to establish toxicological 
trends, like an overall size-dependent toxicity, is therefore hampered by such incon-
sistencies in experimental procedures.
Kim and co-workers (2015) evaluated cytotoxicity of different concentrations of 20, 
60, 100 and 200  nm silica NPs produced by Stöber method in A549 (lung), HepG2 
(liver) and NIH/3T3 (fibroblasts in blood circulation). It was noted that NP toxicity 
was size-, concentration- and cell line-dependent and noted that 60 nm particles were 
preferentially endocytosed by cells and high doses induced a disproportionately large 
decrease in cell viability. While the study was thorough and accounted for a number 
of toxicity endpoints (e.g. ROS, cell membrane integrity), the zeta potential was only 
measured in DI water and varied between − 24 and − 38 mV for the 4 sizes of NP, but 
would have been further improved by measuring in more biologically relevant media.
Zielinski et  al. explored potential side effects of using their silica NP-embed-
ded biodegradable scaffolds intended for laser-tissue-soldering of blood vessels 
in the brain. It was presumed that upon scaffold degradation the silica NPs would 
be released into surrounding brain tissue and uptaken by cells, thus possibly caus-
ing unintended neurotoxicity. The negatively charged NPs were coated with either 
ICG/poly (ε-caprolactone) or ICG/poly (ε-caprolactone-poly l-lactide) and oxidative 
stress was induced in microglial cells, thereby potentially contributing to neuronal 
injury (Koch et al. 2014). Further investigations highlighted that the same NPs were 
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predominantly uptaken via macropinocytosis and phagocytosis and were detected 
in the lysosomes and the endoplasmic reticulum after 4 h exposure (Zielinskia et al. 
2016). Another study investigating in  vitro neurodegeneration demonstrated that 
ICG/poly (ε-caprolactone)-coated silica NPs affected mitochondrial function in 
model SH-SY5Y cells during differentiation, with the authors concluding that further 
studies are required to understand the potential for silica NP-induced neurodegen-
eration (Ducray et al. 2017).
Alternative approaches to assess longer-term effects of NP exposure are also 
needed to achieve a better understanding of the potential risks associated with Si NP 
exposure. For example, deviating from cytotoxicity experimentation (which typically 
only last a number of days) and understanding the genetic responses of organisms 
to NP exposure could also be highly useful. This should allow researchers to form 
a more comprehensive perspective on the interaction between nanomaterials and 
biological systems on a longer-term basis. For example, Hu et  al. (2016) performed 
genome-wide analysis to uncover the genetic pathways associated with the toxicity 
their silica NPs induce in zebrafish embryos. The cytotoxic effects of the NPs resulted 
in the alteration of gene expression patterns associated with various biological pro-
cesses, including immune response, response to stimuli and embryonic development. 
Overall, the expression of 2515 genes were altered, with 1107 being up-regulated and 
1408 down-regulated. Similar studies need to be more widely performed such that a 
broader insight into the biological impacts of nanomaterials can be obtained.
The majority of toxicity studies also usually ignore how the protein corona influences 
NP–cell interactions despite strong evidence suggesting that it can (Corbo et al. 2016). 
For example, an interesting study by Wang et al. (2017) demonstrated how 100 nm silica 
NPs, when exposed to lung tissue, specifically bind transforming growth factor β1 (TGF-
β1) in their protein corona and ultimately induces the development of lung fibrosis in 
murine models. The high concentration of TGF-β1 in the silica NP corona prolonged 
activation of the TGF-β/Smad2 pathway, which promotes tissues fibrosis. Specifically, 
the authors suggest that occupational lung diseases like silicosis could potentially be 
initiated by the corona composition, and demonstrate how the corona formation on 
NPs can adversely induce pathological changes in biological systems. In fact, to further 
complicate matters, a report has shown that the common methods used to isolate NP–
corona complexes (prior to removal of the proteins from the silica NP surface) can influ-
ence the abundance of certain proteins in the corona and also its rearrangement (Pisani 
et al. 2017).
In addition, major areas toxicology are largely unexplored. For example, it is known 
that the microbiota plays a crucial role in human health and that it’s dysbiosis can be 
linked to different forms of disease (Mohajeri et al. 2018). The risks and potential oppor-
tunities associated with NP–microbiome interactions have only become more heavily 
researched in the recent years but it is clear from studies that forms of dysbiosis occur 
upon encountering nanomaterials (Poh et al. 2018; Bouwmeester et al. 2018). However, It 
is not always clear whether nanoparticles directly cause dysbiosis or whether the effects 
are attributed to their dissolved/molecular form (caused, for example, by nanomaterial 
dissolution), or a combination of both. Considering humans encounter nanoparticulate 
matter over the course of their lives (e.g. in food, cosmetic products), it is likely that 
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microbiota studies will become a core focus of human toxicology in the future. Coupled 
with our increased understanding of the protein corona and its ability to influence bio-
nano interactions, the challenges facing the scientific community to develop safe nano-
materials continue to be non-trivial. More fundamental research into uncovering the 
intricacies of bio-nano interactions is required, and is particularly necessary since the 
material scientists continue to develop increasingly more sophisticated nanomaterials 
for bioapplication before fully considering the associated future risks. To this end, it is 
encouraging to see that regulators are increasingly aware of the hazards posed by nano-
materials intended for human exposure (Halamoda-Kenzaoui et al. 2019).
Conclusion
This review has aimed to summarise important literature associated with silica NP syn-
thesis, functionalisation, bioapplications and the importance of the protein corona. The 
two common synthetic approaches to producing silica NPs, namely Stöber method and 
reverse microemulsion, were described. Considerations associated with silica NPs dop-
ing with fluorophores were also highlighted and different bioconjugation strategies used 
for the creation of biomolecule-coated silica NPs were discussed.
It is clear from the literature that DDSNPs are finding success in biomedical diag-
nostic applications. For fluorescence-based tests, the ability of DDSNs to outperform 
traditional organic fluorophores as reporters has led to their incorporation into point-
of-care devices. DDSNs have also become more commonly employed in bioimaging 
due to the ability to be designed to suit different biological applications that require 
adaptable optical platforms. One particularly exciting development in the application 
of DDSNs has been the emergence of C-dots as promising in vivo optical probes for 
tumour imaging. Additionally, their tendency to accumulate in tumours may mean 
they have the potential to deliver drugs to tumour beds. Indeed, it is also evident that 
success has been found when applying DDNPs to in vivo drug delivery applications, 
most notably AGuIX NPs. However, reports published in mouse models have shown 
promising trends like good biodistribution profiles and rapid tumour reduction, but 
very few DDNPs have been used in human studies (as has been the case for practi-
cally all NP types). For this reason further results of C-dot bioimaging clinical trials in 
humans are much anticipated.
Most strategies for localising NPs in tumour sites are based on the exploitation 
of the EPR effect, a method used in clinically successful liposome formulations like 
Doxil. However, in spite of intensive efforts, very few NP-based imaging or thera-
peutic agents have been translated to the clinic. This may be due, in part, to the 
inaccurate in  vitro and in  vivo models that do not fully replicate human tumoural 
environments (e.g. chemical environment, architecture complexity and interactions 
with other healthy tissues). The more widespread use of improved cancer models is 
therefore needed to ensure more scientists are testing NPs in ‘human-like’ conditions 
(Katt et al. 2016). It is here that further understanding the role played by the protein 
corona on the overall fate of NP in vivo will undoubtedly be necessary when attempt-
ing to predict the NP fate. Additionally, the evaluation of the potential longer-term 
effects of NP interactions with biological systems remains understudied and is an area 
of nano-risk assessment that requires improvement. For example, improved in vitro 
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studies where large scale testing can be performed using human-like conditions will 
prove to be beneficial [e.g. using organoids (Truskey 2018)]. Techniques like grouping 
and read across may also prove useful in avoiding case-by-case studies and streamlin-
ing nanorisk assessments (Oomen et al. 2018; Mech et al. 2019). If progressions are 
made in such areas then the outlook that DDNPs will deliver on their promise and 
contribute to the predicted nano-revolution in healthcare is positive, and it is there-
fore expected that DDSNs will continue to be widely used in bio-nanotechnology.
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